These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 34743319)

  • 61. Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial.
    Sloshower J; Skosnik PD; Safi-Aghdam H; Pathania S; Syed S; Pittman B; D'Souza DC
    J Psychopharmacol; 2023 Jul; 37(7):698-706. PubMed ID: 36938991
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review.
    Prouzeau D; Conejero I; Voyvodic PL; Becamel C; Abbar M; Lopez-Castroman J
    Curr Psychiatry Rep; 2022 Oct; 24(10):573-581. PubMed ID: 35953638
    [TBL] [Abstract][Full Text] [Related]  

  • 63. How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change.
    Zeifman RJ; Wagner AC; Monson CM; Carhart-Harris RL
    J Affect Disord; 2023 Aug; 334():100-112. PubMed ID: 37146908
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effects of psilocybin versus escitalopram on rumination and thought suppression in depression.
    Barba T; Buehler S; Kettner H; Radu C; Cunha BG; Nutt DJ; Erritzoe D; Roseman L; Carhart-Harris R
    BJPsych Open; 2022 Sep; 8(5):e163. PubMed ID: 36065128
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Self-administration of Psilocybin in the Setting of Treatment-resistant Depression.
    Lyons A
    Innov Clin Neurosci; 2022; 19(7-9):44-47. PubMed ID: 36204170
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy.
    Dodd S; Norman TR; Eyre HA; Stahl SM; Phillips A; Carvalho AF; Berk M
    CNS Spectr; 2022 Jul; ():1-11. PubMed ID: 35811423
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees.
    Kiraga MK; Kuypers KPC; Uthaug MV; Ramaekers JG; Mason NL
    Front Psychiatry; 2022; 13():883869. PubMed ID: 35873251
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Music programming for psilocybin-assisted therapy: Guided Imagery and Music-informed perspectives.
    Messell C; Summer L; Bonde LO; Beck BD; Stenbæk DS
    Front Psychol; 2022; 13():873455. PubMed ID: 36467212
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use.
    Gukasyan N; Griffiths RR; Yaden DB; Antoine DG; Nayak SM
    J Psychopharmacol; 2023 Jul; 37(7):707-716. PubMed ID: 37291890
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder.
    Doss MK; Považan M; Rosenberg MD; Sepeda ND; Davis AK; Finan PH; Smith GS; Pekar JJ; Barker PB; Griffiths RR; Barrett FS
    Transl Psychiatry; 2021 Nov; 11(1):574. PubMed ID: 34750350
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.
    Goodwin GM; Aaronson ST; Alvarez O; Arden PC; Baker A; Bennett JC; Bird C; Blom RE; Brennan C; Brusch D; Burke L; Campbell-Coker K; Carhart-Harris R; Cattell J; Daniel A; DeBattista C; Dunlop BW; Eisen K; Feifel D; Forbes M; Haumann HM; Hellerstein DJ; Hoppe AI; Husain MI; Jelen LA; Kamphuis J; Kawasaki J; Kelly JR; Key RE; Kishon R; Knatz Peck S; Knight G; Koolen MHB; Lean M; Licht RW; Maples-Keller JL; Mars J; Marwood L; McElhiney MC; Miller TL; Mirow A; Mistry S; Mletzko-Crowe T; Modlin LN; Nielsen RE; Nielson EM; Offerhaus SR; O'Keane V; Páleníček T; Printz D; Rademaker MC; van Reemst A; Reinholdt F; Repantis D; Rucker J; Rudow S; Ruffell S; Rush AJ; Schoevers RA; Seynaeve M; Shao S; Soares JC; Somers M; Stansfield SC; Sterling D; Strockis A; Tsai J; Visser L; Wahba M; Williams S; Young AH; Ywema P; Zisook S; Malievskaia E
    N Engl J Med; 2022 Nov; 387(18):1637-1648. PubMed ID: 36322843
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.
    Gukasyan N; Davis AK; Barrett FS; Cosimano MP; Sepeda ND; Johnson MW; Griffiths RR
    J Psychopharmacol; 2022 Feb; 36(2):151-158. PubMed ID: 35166158
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression.
    Ling S; Ceban F; Lui LMW; Lee Y; Teopiz KM; Rodrigues NB; Lipsitz O; Gill H; Subramaniapillai M; Mansur RB; Lin K; Ho R; Rosenblat JD; Castle D; McIntyre RS
    CNS Drugs; 2022 Jan; 36(1):17-30. PubMed ID: 34791625
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Increased global integration in the brain after psilocybin therapy for depression.
    Daws RE; Timmermann C; Giribaldi B; Sexton JD; Wall MB; Erritzoe D; Roseman L; Nutt D; Carhart-Harris R
    Nat Med; 2022 Apr; 28(4):844-851. PubMed ID: 35411074
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life.
    Goodwin GM; Aaronson ST; Alvarez O; Atli M; Bennett JC; Croal M; DeBattista C; Dunlop BW; Feifel D; Hellerstein DJ; Husain MI; Kelly JR; Lennard-Jones MR; Licht RW; Marwood L; Mistry S; Páleníček T; Redjep O; Repantis D; Schoevers RA; Septimus B; Simmons HJ; Soares JC; Somers M; Stansfield SC; Stuart JR; Tadley HH; Thiara NK; Tsai J; Wahba M; Williams S; Winzer RI; Young AH; Young MB; Zisook S; Malievskaia E
    J Affect Disord; 2023 Apr; 327():120-127. PubMed ID: 36740140
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Daily briefing: Largest trial shows psilocybin is effective to treat depression.
    Graham F
    Nature; 2021 Nov; ():. PubMed ID: 34764467
    [No Abstract]   [Full Text] [Related]  

  • 77. Psilocybin for the Treatment of Obsessive-Compulsive Disorders.
    Ehrmann K; Allen JJB; Moreno FA
    Curr Top Behav Neurosci; 2022; 56():247-259. PubMed ID: 34784024
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Molecular insights into psychedelic drug action.
    Slocum ST; DiBerto JF; Roth BL
    J Neurochem; 2022 Jul; 162(1):24-38. PubMed ID: 34797943
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study.
    Cavanna F; Muller S; de la Fuente LA; Zamberlan F; Palmucci M; Janeckova L; Kuchar M; Pallavicini C; Tagliazucchi E
    Transl Psychiatry; 2022 Aug; 12(1):307. PubMed ID: 35918311
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Psilocybin targets a common molecular mechanism for cognitive impairment and increased craving in alcoholism.
    Meinhardt MW; Pfarr S; Fouquet G; Rohleder C; Meinhardt ML; Barroso-Flores J; Hoffmann R; Jeanblanc J; Paul E; Wagner K; Hansson AC; Köhr G; Meier N; von Bohlen Und Halbach O; Bell RL; Endepols H; Neumaier B; Schönig K; Bartsch D; Naassila M; Spanagel R; Sommer WH
    Sci Adv; 2021 Nov; 7(47):eabh2399. PubMed ID: 34788104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.